Myomo Inc
$ 1.06
-8.62%
02 Jun - close price
- Market Cap 44,820,800 USD
- Current Price $ 1.06
- High / Low $ 1.17 / 1.05
- Stock P/E N/A
- Book Value 0.30
- EPS -0.36
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.23 %
- ROE -0.98 %
- 52 Week High 3.08
- 52 Week Low 0.60
About
Myomo, Inc., a portable medical robotics company, designs, develops and produces myoelectric braces for people with neuromuscular disorders in the United States. The company is headquartered in Boston, Massachusetts.
Analyst Target Price
$4.32
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-03-09 | 2025-11-10 | 2025-08-11 | 2025-05-07 | 2025-03-10 | 2024-11-06 | 2024-08-06 | 2024-05-08 | 2024-03-07 | 2023-11-07 | 2023-08-09 |
| Reported EPS | -0.091 | -0.0852 | -0.09 | -0.12 | -0.08 | -0.01 | -0.03 | -0.03 | -0.1 | -0.07 | -0.06 | -0.04 |
| Estimated EPS | -0.086 | -0.084 | -0.11 | -0.1 | -0.1 | -0.0233 | -0.04 | -0.07 | -0.1 | -0.06 | -0.09 | -0.03 |
| Surprise | -0.005 | -0.0012 | 0.02 | -0.02 | 0.02 | 0.0133 | 0.01 | 0.04 | 0 | -0.01 | 0.03 | -0.01 |
| Surprise Percentage | -5.814% | -1.4286% | 18.1818% | -20% | 20% | 57.0815% | 25% | 57.1429% | 0% | -16.6667% | 33.3333% | -33.3333% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MYO
2026-06-01 12:40:30
Myomo director Thomas Kirk recently purchased 25,000 shares of company stock for $24,825, increasing his total holdings to 653,863 shares. This open market acquisition on May 28, 2026, coincided with a 22% return for the medical robotics company over the past three months. Despite a recent stock decline after positive Q1 2026 earnings, InvestingPro analysis suggests Myomo shares are undervalued.
2026-06-01 12:10:07
Thomas F. Kirk, a director at Myomo (MYO), recently purchased 25,000 shares of the company's common stock for $24,825 at an average price of $0.993 per share. This transaction follows the company's strong performance, with a 22% return over the past three months, and coincides with Myomo's positive Q1 2026 earnings report where EPS and revenue surpassed expectations. Despite an after-hours stock decline post-earnings, InvestingPro's Fair Value assessment suggests the stock is undervalued.
2026-06-01 12:10:07
Myomo (MYO) director F. Kirk reported an open-market purchase of 25,000 shares of Common Stock on May 28, 2026, at $0.993 per share. This transaction increased his direct holdings to 653,863 shares. The Form 4 filing indicates a neutral impact and positive sentiment regarding the insider trade.
2026-05-29 02:08:52
Harry Kovelman, Chief Medical Officer at MYOMO, INC. (NASDAQ:MYO), recently sold $32,239 worth of company common stock through open market transactions on May 27 and May 28, 2026. Following these sales, Kovelman directly holds 108,618 shares of MYO. The insider sale comes as MYO stock trades at $1.09, showing a strong 22% return over the last three months, despite the company quickly burning through cash.
2026-05-29 02:08:52
MYOMO, INC.'s Chief Medical Officer, Harry Kovelman, sold a total of 32,000 shares of company common stock in open-market trades on May 27 and May 28, 2026. The shares were sold at weighted average prices of $1.002 and $1.0172, respectively, totaling $32,239. Following these transactions, Kovelman retains direct ownership of 108,618 shares.
2026-05-28 23:02:00
Harry Kovelman, Chief Medical Officer at a Myomo Inc subsidiary, sold 32,000 shares of Myomo Inc (MYO) on May 28, 2026, reducing his holdings to 108,618 shares. This transaction marks the first insider sell within the last year, compared to 10 insider buys. The company, which develops medical robotics for neuromuscular disorders, saw its shares trading at $1.01, significantly below its GF Value of $3.10, indicating a "Possible Value Trap."
